Results 41 to 50 of about 3,123 (163)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience

Antibiotics, 2022
Background: Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant Staphylococcus aureus (MRSA). Methods: We retrospectively
Maria Mazzitelli, Milo Gatti, Vincenzo Scaglione, Daniele Mengato, Marco Trevenzoli, Andrea Sattin, Federico Pea, Anna Maria Cattelan   +7 more
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie International Edition, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +1 more source

Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU

, 2022
Dalbavancin is a lipoglycopeptide antibiotic used off-label to treat serious gram-positive infections, including infections secondary to methicillin-resistant Staphylococcus aureus (MRSA).
Aggarwal, Abhimanyu, MD, Schimmel, Jennifer, MD, Ritchie, Hannah, Lorenzo, Michael   +3 more
core   +1 more source

Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections

Journal of Global Antimicrobial Resistance, 2021
Objectives: In this meta-analysis, we assessed the clinical efficacy and safety of dalbavancin compared with commonly used anti-Gram-positive agents. Methods: PubMed, Embase and Cochrane Library databases were searched from inception up to 25 February ...
Yuhang Wang, Jin Wang, Rui Wang, Yuanyuan Li, Yun Cai   +4 more
doaj   +1 more source

Projected health‐service cost impact of dalbavancin consolidation therapy for Staphylococcus aureus bacteraemia in an Australian public health system

Internal Medicine Journal, EarlyView.
Abstract Background Management of Staphylococcus aureus bacteraemia (SAB) requires prolonged intravenous (IV) antibiotic therapy delivered in hospital or through Hospital in the Home (HITH), often requiring peripherally inserted central catheters (PICCs) and substantial healthcare resources.
Eli Dunn, Yolande Lindsay, Ian Marr, Fabian Chiong   +3 more
wiley   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3646-3655, October 2026.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections

Antibiotics, 2023
Dalbavancin represents a promising treatment for cardiovascular prosthetic infections due to its prolonged half-life, bactericidal activity, large spectrum of activity, and excellent biofilm penetration. However, the use of dalbavancin in this setting is
Altea Gallerani, Milo Gatti, Andrea Bedini, Stefania Casolari, Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, Alessandra Soffritti, Federico Pea, Cristina Mussini, Marianna Meschiari   +14 more
doaj   +1 more source

Integrated one‐pot CRISPR‐Cas detection: Addressing strategies and future prospects

Interdisciplinary Medicine, Volume 4, Issue 5, September 2026.
Integrated one‐pot CRISPR‐Cas detection significantly simplifies workflows, reduces cross‐contamination risks, and shortens turnaround times, making it highly suitable for point‐of‐care testing (POCT) and resource‐limited settings. Key challenges include system compatibility issues between Cas proteins and isothermal amplification, limited multiplexing
Jian Zhou, Xuemei Ren, Yingjie Ren, Ruiping Wu, Ruiman Geng, Le Chen, Zhuo Li   +6 more
wiley   +1 more source

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

International Journal of Infectious Diseases, 2019
Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years.
Maya Azrad, Motti Baum, Assaf Rokney, Yish Levi, Avi Peretz   +4 more
doaj   +1 more source

Simultaneous Quantification and Pharmacokinetic Study of Five Homologs of Dalbavancin in Rat Plasma Using UHPLC-MS/MS

Molecules, 2020
Dalbavancin is a novel semisynthetic glycopeptide antibiotic that comprises multiple homologs and isomers of similar polarities. However, pharmacokinetic studies have only analyzed the primary components of dalbavancin, namely B0 and B1.
Difeng Zhu, Li Ping, Yawen Hong, Jiale Shen, Qinjie Weng, Qiaojun He   +5 more
doaj   +1 more source